Kura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia

Reuters

Nov 03, 2025

<a href="https://laohu8.com/S/KURA">Kura Oncology</a> Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia

Kura Oncology Inc. and Kyowa Kirin Co., Ltd. announced that new clinical trial results for ziftomenib, an investigational oral menin inhibitor, will be presented at the American Society of Hematology $(ASH)$ 2025 Annual Meeting on December 8, 2025. The data from the KOMET-007 Phase 1a/b study will be featured in two oral presentations, covering the use of ziftomenib in combination with venetoclax and azacitidine in both newly diagnosed and relapsed or refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). The presentations will include updated safety and clinical activity results, with more mature data and expanded safety summaries. Copies of the presentations will be available on Kura Oncology's website following the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567013-en) on November 03, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580219499"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580219499\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580219499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580219499","market":"us","top_or_hot":-1,"title":"Kura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KURA\">Kura Oncology</a> Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kura Oncology Inc. and Kyowa Kirin Co., Ltd. announced that new clinical trial results for ziftomenib, an investigational oral menin inhibitor, will be presented at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> 2025 Annual Meeting on December 8, 2025. The data from the KOMET-007 Phase 1a/b study will be featured in two oral presentations, covering the use of ziftomenib in combination with venetoclax and azacitidine in both newly diagnosed and relapsed or refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). The presentations will include updated safety and clinical activity results, with more mature data and expanded safety summaries. Copies of the presentations will be available on Kura Oncology's website following the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567013-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KURA\">Kura Oncology</a> Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kura Oncology Inc. and Kyowa Kirin Co., Ltd. announced that new clinical trial results for ziftomenib, an investigational oral menin inhibitor, will be presented at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> 2025 Annual Meeting on December 8, 2025. The data from the KOMET-007 Phase 1a/b study will be featured in two oral presentations, covering the use of ziftomenib in combination with venetoclax and azacitidine in both newly diagnosed and relapsed or refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). The presentations will include updated safety and clinical activity results, with more mature data and expanded safety summaries. Copies of the presentations will be available on Kura Oncology's website following the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567013-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5hhhVy:1","article_id":"2580219499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580219499","pubTimestamp":1762179264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kura Oncology Inc. and Kyowa Kirin Co., Ltd. announced that new clinical trial results for ziftomenib, an investigational oral menin inhibitor, will be presented at the American Society of Hematology  2025 Annual Meeting on December 8, 2025. The data from the KOMET-007 Phase 1a/b study will be featured in two oral presentations, covering the use of ziftomenib in combination with venetoclax and azacitidine in both newly diagnosed and relapsed or refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia . The presentations will include updated safety and clinical activity results, with more mature data and expanded safety summaries. Copies of the presentations will be available on Kura Oncology's website following the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","KURA":"Kura Oncology, Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Kura Oncology宣布Ziftomenib联合治疗急性髓系白血病的积极1b期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"KURA":0.9},"content_text":"Kura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia\n    \n\n        Kura Oncology Inc. and Kyowa Kirin Co., Ltd. announced that new clinical trial results for ziftomenib, an investigational oral menin inhibitor, will be presented at the American Society of Hematology $(ASH)$ 2025 Annual Meeting on December 8, 2025. The data from the KOMET-007 Phase 1a/b study will be featured in two oral presentations, covering the use of ziftomenib in combination with venetoclax and azacitidine in both newly diagnosed and relapsed or refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). The presentations will include updated safety and clinical activity results, with more mature data and expanded safety summaries. Copies of the presentations will be available on Kura Oncology's website following the meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567013-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}